Common Side Effects of GLP-1 Agonists: What Patients Need to Know

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

GLP-1 agonists commonly cause nausea, vomiting, and diarrhea, especially at treatment start. Patients should monitor symptoms and consult their healthcare provider for management. Always seek medical advice.

# Common Side Effects of GLP-1 Agonists: What Patients Need to Know

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications increasingly used to manage type 2 diabetes and obesity. These drugs mimic the action of the GLP-1 hormone, which stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety. Popular agents include exenatide, liraglutide, dulaglutide, and semaglutide.

While GLP-1 agonists offer significant benefits in glycemic control and weight loss, they are also associated with side effects that patients should understand. This article provides an evidence-based overview of common side effects, practical dosing considerations, and guidelines for patients starting GLP-1 therapy.

---

How GLP-1 Agonists Work

GLP-1 is an incretin hormone released from the gut in response to food intake. It enhances insulin secretion by pancreatic beta cells and reduces glucagon secretion from alpha cells, helping lower blood glucose levels. Additionally, GLP-1 delays gastric emptying and increases feelings of fullness, aiding weight management.

GLP-1 agonists are injectable medications that activate the GLP-1 receptor, producing similar effects to natural GLP-1 but with longer duration.

---

Common Side Effects of GLP-1 Agonists

1. Gastrointestinal Symptoms

Nausea, vomiting, diarrhea, and constipation are the most frequently reported side effects. These occur because GLP-1 agonists slow gastric emptying and affect gut motility.

  • Nausea is reported in up to 30-50% of patients, especially during the first few weeks of treatment.
  • Vomiting and diarrhea occur less frequently but can be bothersome.
  • Symptoms often improve over time as the body adjusts.
  • Starting at a low dose and gradual titration can reduce gastrointestinal intolerance.

    • Evidence: A meta-analysis of randomized controlled trials found that nausea was the leading adverse event associated with GLP-1 agonists, but it was mostly mild to moderate and transient (Zhao et al., 2019).

    2. Hypoglycemia

    GLP-1 agonists themselves have a low risk of causing hypoglycemia when used alone because their insulinotropic effect is glucose-dependent. However, when combined with other antidiabetic agents such as sulfonylureas or insulin, the risk of low blood sugar increases.

  • Patients should monitor blood glucose regularly.
  • Dose adjustments of concomitant hypoglycemic drugs may be necessary.

    • 3. Injection Site Reactions

    Some patients experience redness, swelling, itching, or discomfort at the injection site. These reactions are generally mild and transient.

    4. Pancreatitis (Rare but Serious)

    Cases of acute pancreatitis have been reported, although causality remains controversial. Patients should be informed of the signs, including severe abdominal pain, nausea, and vomiting, and seek medical attention immediately if they occur.

    Clinical guidance: GLP-1 agonists are generally avoided in patients with a history of pancreatitis.

    5. Other Potential Side Effects

  • Gallbladder disease: Some studies suggest an increased risk of gallstones and cholecystitis.
  • Renal effects: Volume depletion from vomiting or diarrhea may worsen kidney function in susceptible individuals.
  • Thyroid C-cell tumors: Observed in rodents but not confirmed in humans; GLP-1 agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma.

    • ---

    Practical Protocol Information and Dosing Examples

    Dosing regimens vary by specific GLP-1 agonist, but a general principle is to start low and titrate slowly to minimize side effects.

    | Medication | Typical Starting Dose | Maintenance Dose Range |

    |----------------|----------------------------------------|------------------------------------|

    | Exenatide | 5 mcg subcutaneously twice daily | 10 mcg twice daily |

    | Liraglutide | 0.6 mg once daily for 1 week | Up to 1.8 mg once daily |

    | Dulaglutide | 0.75 mg once weekly | Up to 1.5 mg once weekly